Thrivent Financial For Lutherans decreased its holdings in Bristol-Myers Squibb Company (NYSE:BMY) by 97.1% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 65,973 shares of the biopharmaceutical company’s stock after selling 2,196,530 shares during the quarter. Thrivent Financial For Lutherans’ holdings in Bristol-Myers Squibb were worth $3,676,000 as of its most recent filing with the SEC.
Other hedge funds have also made changes to their positions in the company. Franklin Resources Inc. increased its position in shares of Bristol-Myers Squibb by 185.2% during the 2nd quarter. Franklin Resources Inc. now owns 6,098,935 shares of the biopharmaceutical company’s stock worth $339,830,000 after purchasing an additional 3,960,191 shares in the last quarter. Ameriprise Financial Inc. increased its position in shares of Bristol-Myers Squibb by 18.7% during the 1st quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock worth $845,504,000 after purchasing an additional 2,451,390 shares in the last quarter. BlackRock Inc. increased its position in shares of Bristol-Myers Squibb by 2.4% during the 2nd quarter. BlackRock Inc. now owns 99,454,602 shares of the biopharmaceutical company’s stock worth $5,541,612,000 after purchasing an additional 2,367,864 shares in the last quarter. State Street Corp increased its position in shares of Bristol-Myers Squibb by 1.8% during the 1st quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock worth $3,746,446,000 after purchasing an additional 1,223,457 shares in the last quarter. Finally, Jennison Associates LLC increased its position in shares of Bristol-Myers Squibb by 5.4% during the 2nd quarter. Jennison Associates LLC now owns 23,118,789 shares of the biopharmaceutical company’s stock worth $1,288,179,000 after purchasing an additional 1,184,652 shares in the last quarter. Institutional investors own 69.82% of the company’s stock.
In other news, EVP Sandra Leung sold 156,582 shares of the firm’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $63.37, for a total value of $9,922,601.34. Following the transaction, the executive vice president now owns 584,373 shares of the company’s stock, valued at approximately $37,031,717.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.23% of the stock is currently owned by company insiders.
Bristol-Myers Squibb Company (NYSE BMY) opened at $60.97 on Thursday. The stock has a market cap of $101,508.14, a PE ratio of 20.95, a PEG ratio of 2.35 and a beta of 1.18. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46. Bristol-Myers Squibb Company has a one year low of $46.01 and a one year high of $66.10.
Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.77 by ($0.02). The business had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.20 billion. Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The firm’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same period last year, the business posted $0.77 EPS. sell-side analysts expect that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Thrivent Financial For Lutherans Sells 2,196,530 Shares of Bristol-Myers Squibb Company (BMY)” was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://www.tickerreport.com/banking-finance/3079173/thrivent-financial-for-lutherans-sells-2196530-shares-of-bristol-myers-squibb-company-bmy.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.